Phaseline

Companies › Beam Therapeutics

Beam Therapeutics: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 5 Phase 1; Hematology, Metabolic and endocrine, Oncology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BEAM-201
Base editing CAR-T cell therapy
–Phase 1Lymphoblastic LymphomaDec 2026
BEAM-301
In vivo base editor targeting G6PC1 c.247C>T allele via A:T-to-G:C base-pair substitution
G6PC1Phase 1Glycogen Storage Disease Type IaDec 2027
BEAM-101
Base edited CD34+ hematopoietic stem and progenitor cells (autologous)
–Phase 1Sickle Cell DiseaseFeb 2028
BEAM-302
lipid nanoparticle (LNP)-based alpha-1 antitrypsin (AAT) gene therapy
SERPINA1Phase 1Alpha 1-Antitrypsin DeficiencyMay 2028
BEAM-103
Monoclonal antibody
–Phase 1Healthy Subjects–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07304791BEAM-103Phase 1Healthy SubjectsOtherJan 2026
NCT05885464BEAM-201Phase 1Lymphoblastic LymphomaOncologyDec 2026
NCT06735755BEAM-301Phase 1Glycogen Storage Disease Type IaGenitourinaryDec 2027
NCT05456880BEAM-101Phase 1Sickle Cell DiseaseHematologyFeb 2028
NCT06389877BEAM-302Phase 1Alpha 1-Antitrypsin DeficiencyMetabolic and endocrineMay 2028

From the company's SEC filings

Cash and short-term investments of $1.0bn on 2026-09-30; operating cash outflow about $410m a year; runway about 29 months at that burn, to Mar 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SERPINA1 (1) G6PC1 (1)

Companies with the same targets

Krystal Biotech Takeda Tessera Therapeutics Wave Life Sciences USA Grifols Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.